Recent News

• 09.04.2025 - Grace Therapeutics Announces Presentation at The H.C. Wainwright 27th Annual Global Investment Conference
• 08.27.2025 - Grace Therapeutics Announces U.S. Food and Drug Administration Acceptance for Review of New Drug Application for GTx-104
• 08.12.2025 - Grace Therapeutics Announces First Quarter 2026 Financial Results, Provides Business Update
• 06.25.2025 - Grace Therapeutics Announces Submission of New Drug Application to U.S. Food and Drug Administration for GTx-104
• 06.23.2025 - Grace Therapeutics Announces 2025 Fiscal Year-End Results, Provides Business Update
• 06.13.2025 - Grace Therapeutics to Participate in the 2025 BIO International Conference

Recent Filings

• 08.27.2025 - 8-K Current report
• 08.27.2025 - EX-99.1 EX-99.1
• 08.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 08.12.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.12.2025 - 8-K Current report
• 08.12.2025 - EX-99.1 EX-99.1
• 07.28.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 07.28.2025 - DEF 14A Other definitive proxy statements
• 06.25.2025 - 8-K Current report
• 06.25.2025 - EX-99.1 EX-99.1